Patients with indolent (ISM) or smoldering systemic mastocytosis (SSM) frequently experience significant gastrointestinal symptoms — including abdominal pain, cramping, diarrhea, heartburn, nausea, and vomiting — that require specific, structured management.
This protocol targets ISM and SSM patients presenting with abdominal complaints as a primary concern. Treatment goals in this population are primarily directed toward symptom control and anaphylaxis prevention, alongside management of related complications.
The structured regimen for GI symptom control in this setting centres on a specific class of acid-suppressing therapy. The complete protocol specifies which agents are indicated within that class and the clinical criteria guiding their use.